Swedish sealing expert Roxtec builds electrical safety barrier to help Yangzi Petrochemical refining restructuring
As the domestic petrochemical industry pays increasing attention to production safety, enterprises such as Yangzi Petrochemical are also constantly exploring and practicing, striving to adopt more advanced anti-explosion design in building structure design. Roxtec sealing system, with its reliable safety performance, has become the ideal choice for many chemical companies. It can not only withstand the strong impact of the explosion, but also ensure the structural integrity of the building, so that it maintains its original anti-explosion performance.
View
08
2024
US Stocks Dragon and Tiger News: VISTA halts trials to seek sale, once-a-year weight loss drug rises 270% in one day
New data progress: PSMA/CD3 pro-antibody JANX007 is in phase 1 for the treatment of mCRPC and interim clinical data for EGFR/CD3 pro-antibody JANX008 is in phase 1 for the treatment of solid tumors; GLP-1/GIP receptor agonist VK2735 has phase 2 VENTURE trial results in obese patients; ERK/NFκB inhibitor NE3107 has announced phase 2a data for PD (Parkinson's disease) and phase 3 data for AD (Alzheimer's disease); KIT monoclonal antibody Barzolvolimab has phase 2 12-week results for the treatment of CSU; CD45 iodine RDC Iomab-B is in phase 3 for the treatment of AML and announced phase 3 SIERRA trial results
View
08
2024
Re ding medicine: shout out the next 5 years of revenue CAGR 50%
On May 8,20024, Zaiding Pharmaceutical announced the financial performance of 24Q1, and on May 9, it directly closed with a 20 + CM increase. This was the first time since Zaiding Pharmaceutical was listed in Hong Kong in 2020
View
08
2024
Alex: In the past two years, it has tripled. What about the future?
A single variety, the resignation of the general manager, more than 5% of major shareholders dealing with reducing their holdings for three consecutive years, and construction businessmen as the leaders, all these topics are focused on a young pharmaceutical company - Elise. But even so, it still couldn't stop Ellis from rising from the lowest price of around 15 yuan after its IPO to the latest price of around 60 yuan, and it only took 2 years to achieve a stock price increase of about 3 times from the bottom to now.
View
08
2024